Updates are available Correction dated 2022-07-15
Click to view Correction: https://doi.org/10.1186/s12967-022-03518-0
-
Authors
Helland, Åslaug http://orcid.org/0000-0002-5520-0275
Russnes, Hege G.
Fagereng, Gro Live
Al-Shibli, Khalid
Andersson, Yvonne
Berg, Thomas
Bjørge, Line
Blix, Egil
Bjerkehagen, Bodil
Brabrand, Sigmund
Cameron, Marte Grønlie
Dalhaug, Astrid
Dietzel, Dalia
Dønnem, Tom
Enerly, Espen
Flobak, Åsmund
Fluge, Sverre
Gilje, Bjørnar
Gjertsen, Bjørn Tore
Grønberg, Bjørn Henning
Grønås, Kari
Guren, Tormod
Hamre, Hanne
Haug, Åse
Heinrich, Daniel
Hjortland, Geir Olav
Hovig, Eivind
Hovland, Randi
Iversen, Ann-Charlotte
Janssen, Emiel
Kyte, Jon Amund
von der Lippe Gythfeldt, Hedda
Lothe, Ragnhild
Lund, Jo-Åsmund
Meza-Zepeda, Leonardo
Munthe-Kaas, Monica Cheng
Nguyen, Olav Toai Duc
Niehusmann, Pitt
Nilsen, Hilde
Puco, Katarina
Ree, Anne Hansen
Riste, Tonje Bøyum
Semb, Karin
Steinskog, Eli Sihn Samdal
Stensvold, Andreas
Suhrke, Pål
Tennøe, Øyvind
Tjønnfjord, Geir E.
Vassbotn, Liv Jorunn
Aas, Eline
Aasebø, Kristine
Tasken, Kjetil
Smeland, Sigbjørn
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04817956 at ClinicalTrials.govDocuments that mention this clinical trial
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.
https://doi.org/10.1200/jco.2023.41.16_suppl.e15188
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
https://doi.org/10.1186/s12967-022-03432-5
Rapid label expansion based on public-private collaboration in IMPRESS-Norway.
https://doi.org/10.1200/jco.2024.42.16_suppl.e13529
456 Molecular characteristics of gynaecological cancer patients in the IMPRESS-Norway trial – a national prospective, non-randomized clinical trial evaluating the efficacy of anti-cancer drugs on new indications
https://doi.org/10.1136/ijgc-2024-esgo.1105
-
Funding
Funding for this research was provided by:
Illumina
Klinbeforsk
Kreftforeningen
Radiumhospitalets Forskningsstifltelse
F. Hoffmann-La Roche
InCyte
Novartis Pharma
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 17 March 2022
Accepted: 4 May 2022
First Online: 14 May 2022
Change Date: 15 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12967-022-03518-0
Declarations
:
: The study is approved by the regional ethics committee (REK-Sør-Øst, REK # 200764). Patients have received written and oral information about the study and have signed an informed consent.
: Roche, Novartis, Eli Lilly, Incyte, and Illumina have seen and approved this manuscript.
: This study is supported by several pharmaceutical companies (Roche, Novartis, Eli Lilly, Incyte) in addition to Foundation Medicine and Illumina. None of the authors receive reimbursement or salaries for this study from companies.
